According to the Asia Pacific Pharmaceutical announcement, on January 7, 2026, Fubon Group, the company's former controlling shareholder, and Han Gui Investment completed transfer registration of 14.61% of the shares to Xinghao Holdings and Xing Chen Investment. The transfer price was 8.26 yuan/share, with a total amount of 900 million yuan. After this transfer, the controlling shareholder of the company changed from Fubon Group to Xinghao Holdings, and the actual controller changed from the management team of Song Hanping, Fu Cai, and Hu Zhenghui to Qiu Zhongxun. Xingchen Investment entrusts the voting rights of its 48,420,252 shares to Xinghao Holdings, and the two form the same actors.

According to the Asia Pacific Pharmaceutical announcement, on January 7, 2026, Fubon Group, the company's former controlling shareholder, and Han Gui Investment completed transfer registration of 14.61% of the shares to Xinghao Holdings and Xing Chen Investment. The transfer price was 8.26 yuan/share, with a total amount of 900 million yuan. After this transfer, the controlling shareholder of the company changed from Fubon Group to Xinghao Holdings, and the actual controller changed from the management team of Song Hanping, Fu Cai, and Hu Zhenghui to Qiu Zhongxun. Xingchen Investment entrusts the voting rights of its 48,420,252 shares to Xinghao Holdings, and the two form the same actors.